CN101760566A - 一种hbv基因的核苷酸突变位点的检测方法 - Google Patents
一种hbv基因的核苷酸突变位点的检测方法 Download PDFInfo
- Publication number
- CN101760566A CN101760566A CN 200910178449 CN200910178449A CN101760566A CN 101760566 A CN101760566 A CN 101760566A CN 200910178449 CN200910178449 CN 200910178449 CN 200910178449 A CN200910178449 A CN 200910178449A CN 101760566 A CN101760566 A CN 101760566A
- Authority
- CN
- China
- Prior art keywords
- seq
- extension
- primer
- site
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 42
- 108091028664 Ribonucleotide Proteins 0.000 title 1
- 239000002336 ribonucleotide Substances 0.000 title 1
- 125000002652 ribonucleotide group Chemical group 0.000 title 1
- 238000006243 chemical reaction Methods 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 44
- 102000004190 Enzymes Human genes 0.000 claims abstract description 40
- 108090000790 Enzymes Proteins 0.000 claims abstract description 40
- 239000011347 resin Substances 0.000 claims abstract description 20
- 229920005989 resin Polymers 0.000 claims abstract description 20
- 238000000746 purification Methods 0.000 claims abstract description 12
- 241000700721 Hepatitis B virus Species 0.000 claims description 58
- 230000000869 mutational effect Effects 0.000 claims description 48
- 125000003729 nucleotide group Chemical group 0.000 claims description 42
- 239000002773 nucleotide Substances 0.000 claims description 41
- 238000013461 design Methods 0.000 claims description 21
- 230000002103 transcriptional effect Effects 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000013642 negative control Substances 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 9
- 239000011159 matrix material Substances 0.000 claims description 9
- 238000002288 cocrystallisation Methods 0.000 claims description 8
- 239000013641 positive control Substances 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000004907 flux Effects 0.000 abstract description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 239000000047 product Substances 0.000 description 65
- 239000000523 sample Substances 0.000 description 51
- 239000002585 base Substances 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 32
- 238000001819 mass spectrum Methods 0.000 description 23
- 239000003814 drug Substances 0.000 description 22
- 108020004705 Codon Proteins 0.000 description 21
- 230000035772 mutation Effects 0.000 description 16
- 230000003321 amplification Effects 0.000 description 13
- 238000003199 nucleic acid amplification method Methods 0.000 description 13
- 239000012264 purified product Substances 0.000 description 13
- 238000013016 damping Methods 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 229960001997 adefovir Drugs 0.000 description 6
- 229960001627 lamivudine Drugs 0.000 description 6
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 230000004304 visual acuity Effects 0.000 description 6
- 241000238557 Decapoda Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000030609 dephosphorylation Effects 0.000 description 5
- 238000006209 dephosphorylation reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960000980 entecavir Drugs 0.000 description 5
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108010013043 Acetylesterase Proteins 0.000 description 4
- 108010000178 IGF-I-IGFBP-3 complex Proteins 0.000 description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 238000010612 desalination reaction Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 4
- -1 271.2Da Chemical compound 0.000 description 3
- 101000690100 Homo sapiens U1 small nuclear ribonucleoprotein 70 kDa Proteins 0.000 description 3
- 102100024121 U1 small nuclear ribonucleoprotein 70 kDa Human genes 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002360 explosive Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960005311 telbivudine Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
引物 | 延伸引物反应浓度(μM/9μl反应体系) |
180 | 0.715 |
204 | 0.814 |
250 | 0.831 |
184 | 0.844 |
236 | 0.997 |
181#1#1 | 0.721 |
181#2#1 | 0.798 |
202 | 0.829 |
181#1#2 | 0.718 |
181#2#2 | 0.729 |
204#1 | 0.819 |
184#2 | 0.793 |
引物名称 | 延伸引物序列 |
180 | GCCTCAGTCCGTTTCTC (SEQ ID NO:4) |
204 | CCCCCAATACCACATCATC (SEQ ID NO:10) |
250 | GGGCTACTCCCTTAACTTC (SEQ ID NO:11) |
184 | ACTGAACAAATGGCACTAC (SEQ ID NO:12) |
181#1#1 | TCAGTCCGTTTCTCTTG (SEQ ID NO:5) |
181#1#2 | TCAGTCCGTTTCTCCTG (SEQ ID NO:6) |
181#2#1 | ATGGCACTAGTAAACTGA (SEQ ID NO:8) |
181#2#2 | TGGCACTACCAAACTGA (SEQ ID NO:9) |
236 | GTCTTTGGGTATACATTTAA (SEQ ID NO:13) |
202 | CCCACTGTTTGGCTTTCA (SEQ ID NO:14) |
204#1 | CCCAATACCACATCATCCA (SEQ ID NO:15) |
184#2 | ACTGAACAAATGGCACTA (SEQ ID NO:16) |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910178449.6A CN101760566B (zh) | 2008-12-12 | 2009-09-29 | 一种hbv基因的核苷酸突变位点的检测方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810218344.4 | 2008-12-12 | ||
CNA2008102183444A CN101440407A (zh) | 2008-12-12 | 2008-12-12 | 一种核苷酸突变位点的检测方法 |
CN200910178449.6A CN101760566B (zh) | 2008-12-12 | 2009-09-29 | 一种hbv基因的核苷酸突变位点的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101760566A true CN101760566A (zh) | 2010-06-30 |
CN101760566B CN101760566B (zh) | 2014-01-15 |
Family
ID=42491944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910178449.6A Active CN101760566B (zh) | 2008-12-12 | 2009-09-29 | 一种hbv基因的核苷酸突变位点的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101760566B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012100369A1 (zh) * | 2011-01-26 | 2012-08-02 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种检测消化道病原体的方法 |
WO2013049975A1 (zh) * | 2011-10-08 | 2013-04-11 | 深圳华大基因科技有限公司 | 检测dna样品中预定位点的突变的试剂盒、方法及应用 |
CN103184270A (zh) * | 2011-12-28 | 2013-07-03 | 北京宏微特斯生物科技有限公司 | 检测结核分枝杆菌(tb)的耐药基因突变型的方法和试剂盒 |
CN106834455A (zh) * | 2017-01-17 | 2017-06-13 | 北京大学第医院 | 一种检测HBeAg阴性HBV慢性感染肝硬化者的肝癌易感基因的试剂盒及方法 |
CN110923359A (zh) * | 2019-11-29 | 2020-03-27 | 中国食品药品检定研究院 | 检测ⅰ型脊灰减毒活疫苗核酸突变的质谱检测引物组及其方法 |
CN111118141A (zh) * | 2020-01-15 | 2020-05-08 | 浙江迪谱诊断技术有限公司 | 一种用于葡萄糖-6-磷酸脱氢酶(g6pd)基因突变检测的引物序列及试剂盒 |
CN111154914A (zh) * | 2019-12-03 | 2020-05-15 | 阔然医学检验实验室(徐州)有限公司 | 一种快速检测乙肝肝炎病毒耐药位点的试剂盒及其使用方法 |
CN116949223A (zh) * | 2023-09-19 | 2023-10-27 | 广东凯普生物科技股份有限公司 | 一种乙型肝炎病毒用药指导系统及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1393567A (zh) * | 2001-06-27 | 2003-01-29 | 军事医学科学院放射医学研究所 | 乙型肝炎病毒耐药检测寡核苷酸基因芯片的制备和用途 |
-
2009
- 2009-09-29 CN CN200910178449.6A patent/CN101760566B/zh active Active
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012100369A1 (zh) * | 2011-01-26 | 2012-08-02 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种检测消化道病原体的方法 |
CN103210093A (zh) * | 2011-01-26 | 2013-07-17 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种检测消化道病原体的方法 |
CN103210093B (zh) * | 2011-01-26 | 2015-02-18 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种检测消化道病原体的方法 |
WO2013049975A1 (zh) * | 2011-10-08 | 2013-04-11 | 深圳华大基因科技有限公司 | 检测dna样品中预定位点的突变的试剂盒、方法及应用 |
CN103184270A (zh) * | 2011-12-28 | 2013-07-03 | 北京宏微特斯生物科技有限公司 | 检测结核分枝杆菌(tb)的耐药基因突变型的方法和试剂盒 |
CN106834455B (zh) * | 2017-01-17 | 2021-02-09 | 北京大学第一医院 | 一种检测HBeAg阴性HBV慢性感染肝硬化者的肝癌易感基因的试剂盒及方法 |
CN106834455A (zh) * | 2017-01-17 | 2017-06-13 | 北京大学第医院 | 一种检测HBeAg阴性HBV慢性感染肝硬化者的肝癌易感基因的试剂盒及方法 |
CN110923359A (zh) * | 2019-11-29 | 2020-03-27 | 中国食品药品检定研究院 | 检测ⅰ型脊灰减毒活疫苗核酸突变的质谱检测引物组及其方法 |
CN111154914A (zh) * | 2019-12-03 | 2020-05-15 | 阔然医学检验实验室(徐州)有限公司 | 一种快速检测乙肝肝炎病毒耐药位点的试剂盒及其使用方法 |
CN111118141A (zh) * | 2020-01-15 | 2020-05-08 | 浙江迪谱诊断技术有限公司 | 一种用于葡萄糖-6-磷酸脱氢酶(g6pd)基因突变检测的引物序列及试剂盒 |
CN111118141B (zh) * | 2020-01-15 | 2023-09-01 | 浙江迪谱诊断技术有限公司 | 一种用于葡萄糖-6-磷酸脱氢酶(g6pd)基因突变检测的引物序列及试剂盒 |
CN116949223A (zh) * | 2023-09-19 | 2023-10-27 | 广东凯普生物科技股份有限公司 | 一种乙型肝炎病毒用药指导系统及其应用 |
CN116949223B (zh) * | 2023-09-19 | 2023-12-29 | 广东凯普生物科技股份有限公司 | 一种乙型肝炎病毒用药指导系统及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101760566B (zh) | 2014-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101760566B (zh) | 一种hbv基因的核苷酸突变位点的检测方法 | |
USRE46293E1 (en) | System and method for detection of HIV tropism variants | |
CN102912036B (zh) | 快速检测和鉴定生物物体的方法 | |
CN1774511B (zh) | 用于序列变异检测和发现的基于断裂的方法和系统 | |
CN101838683B (zh) | 一种kras基因和/或braf基因的核苷酸突变位点的检测方法 | |
JP2009502137A (ja) | 核酸変種の迅速な同定および定量のための方法 | |
CN102181575A (zh) | 用于检测乙型肝炎病毒耐药突变位点的引物及方法 | |
CN106835292B (zh) | 一步法快速构建扩增子文库的方法 | |
CN101440407A (zh) | 一种核苷酸突变位点的检测方法 | |
CN103261437B (zh) | 用于hpa基因分型的方法及所用引物 | |
KR102121570B1 (ko) | 인삼 품종 또는 자원의 판별 및 분류를 위한 snp 기반 kasp용 프라이머 세트 및 이의 용도 | |
CN107012139A (zh) | 一种快速构建扩增子文库的方法 | |
CN108165618B (zh) | 一种包含核苷酸和3’端可逆封闭核苷酸的dna测序方法 | |
EP2013366B1 (en) | Sequencing of the L10 codon of the HIV gag gene | |
EP2333104A1 (en) | RNA analytics method | |
CN115109843A (zh) | 一种多个水稻性状控制基因变异检测功能标记方法 | |
KR101254663B1 (ko) | 파이로시퀀싱을 이용한 신종 인플루엔자 바이러스의 항바이러스제에 대한 유전자의 내성 돌연변이 검출방법 | |
CN114875118B (zh) | 确定细胞谱系的方法、试剂盒和装置 | |
CN115418394A (zh) | 用于检测cho细胞基因组dna的组合物、试剂盒及方法 | |
CN111500782B (zh) | 一种新型hiv-1逆转录酶耐药突变位点检测方法的建立及应用 | |
CN108330213B (zh) | 一种同时进行hbv dna定量、基因分型及rt区突变检测方法 | |
CN109609694B (zh) | 基于Illumina测序技术检测乙型肝炎分型及多耐药位点的试剂盒及方法 | |
CN116814777B (zh) | 高血压用药指导相关基因多态位点的试剂盒及其使用方法 | |
CN105648084A (zh) | 一种两核苷酸实时合成测序检测碱基连续突变序列的方法 | |
CN117025803A (zh) | 一种用于检测结核分枝杆菌利福平耐药基因型的方法及检测产品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1142635 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN BEIJING GENOMICS INSTITUTE HEALTH TECHNOL Free format text: FORMER OWNER: BGI-SHENZHEN CO., LTD. Effective date: 20131127 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20131127 Address after: Yantian District of Shenzhen City, Guangdong province 518083 North Road No. 146 North Industrial Zone 11, floor 3, 2 Applicant after: BGI HEALTH SERVICE Co.,Ltd. Address before: 11, 8 floor, Beishan Industrial Zone, Yantian District, Guangdong, Shenzhen 518083, China Applicant before: BGI SHENZHEN Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CI01 | Publication of corrected invention patent application |
Correction item: Address information of the patent holder Correct: 2, 3 floor, Beishan Industrial Zone, 146 North Mountain Road, Yantian District, Shenzhen, Guangdong, False: Floor 11, building 8, Beishan Industrial Zone, Yantian District, Shenzhen, Guangdong Number: 03 Volume: 30 |
|
CI01 | Publication of corrected invention patent application | ||
CI03 | Correction of invention patent | ||
CI03 | Correction of invention patent |
Correction item: Address of the patentee Correct: 2, 3 floor, Beishan Industrial Zone, 146 North Mountain Road, Yantian District, Shenzhen, Guangdong, False: Error Number: 03 Page: The title page Volume: 30 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1142635 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee |
Owner name: SHENZHEN BGI CORPORATION Free format text: FORMER NAME: SHENZHEN BGI MEDICINE CO., LTD. Owner name: SHENZHEN BGI MEDICINE CO., LTD. Free format text: FORMER NAME: SHENZHEN BEIJING GENOMICS INSTITUTE HEALTH TECHNOLOGY CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Yantian District of Shenzhen City, Guangdong province 518083 North Road No. 146 North Industrial Zone 11, floor 3, 2 Patentee after: BGI SHENZHEN Co.,Ltd. Address before: Yantian District of Shenzhen City, Guangdong province 518083 North Road No. 146 North Industrial Zone 11, floor 3, 2 Patentee before: BGI DIAGNOSIS Co.,Ltd. Address after: Yantian District of Shenzhen City, Guangdong province 518083 North Road No. 146 North Industrial Zone 11, floor 3, 2 Patentee after: BGI DIAGNOSIS Co.,Ltd. Address before: Yantian District of Shenzhen City, Guangdong province 518083 North Road No. 146 North Industrial Zone 11, floor 3, 2 Patentee before: BGI HEALTH SERVICE Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230510 Address after: 100094 rooms 236 and 237, building 1, 538 yongfengtun, Haidian District, Beijing Patentee after: BEIJING GBI BIOTECHNOLOGY Co.,Ltd. Patentee after: BGI SHENZHEN Co.,Ltd. Address before: 518083, 2nd and 3rd floors, Building 11, Beishan Industrial Zone, No. 146 Beishan Road, Yantian District, Shenzhen, Guangdong Province Patentee before: BGI SHENZHEN Co.,Ltd. |
|
TR01 | Transfer of patent right |